TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00535041
Drug: Chemotherapy, radiation therapy & surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: radiation and chemotherapy
Study: NCT00097110
Drug: Vitamin C and E
Normalized name: Balanced B-Complex with Vitamin C and E
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00122447
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical placebo for each active comparator:~placebo aspirin 325 mg PO QD; placebo for alpha lipoic acid 600 mg PO BID; placebo for olmesartan 40 mg PO QD
Study: NCT03432091
Drug: melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ramelteon RMT (RMT, Rozerem®), a novel MT1 and MT2 agonist, has been approved for treatment of insomnia, and provides a strong phase shift signal to the circadian timing system. Melatonin receptor agonists have recently become available for treatment of sleep and psychiatric disorders
Study: NCT00883935
Drug: GSK1349572
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1349572 30 mg once a day for 5 days in Period 1 and 14 days in Period 2
Study: NCT00814606
Drug: Fluvastatin
Normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Week 1: Fluvastatin 20mg daily Week 3: Fluvastatin 40mg daily Week 5: Fluvastatin 60mg daily Week 7: Fluvastatin 80 mg daily
Study: NCT03084809
Drug: FOLFOX4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 1: Oxaliplatin 130 mg/m² IV infusion in 500 mL D5W. Day 2-6: leucovorin 200mg/m² IV infusion in D5W both given over 2 hours at the same time in separate bags Day 2-6: 5-FU 500 mg/m² IV bolus given continuously over 4-6 hours. The treatment is given for 4-6 cycles, every 3 weeks.
Study: NCT00799708
Drug: Comparator: Estrace
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrace 0.5 mg or 2 mg tablets once daily for 7 days.
Study: NCT00880334
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken orally once a day every day
Study: NCT03343639
Drug: Matching Placebo Tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Tablets
Study: NCT00560924
Drug: estradiol, 25 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01613729
Drug: Rosuvastatin 5 mg
Normalized name: rosuvastatin 5 MG
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin 5 mg
Study: NCT01613729
Drug: Rosuvastatin 10 mg
Normalized name: rosuvastatin 10 MG
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00812318
Drug: GSK1265744 10 mg oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1265744
Study: NCT00812318
Drug: GSK1265744 5 mg tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1265744 5mg tablet, fasted
Study: NCT00812318
Drug: GSK1265744 5 mg tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1265744 5mg tablet, fed
Study: NCT01091766
Drug: intravenous injection of test solution
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: test dose consists of 0.2 ml/kg body weight test solution of the assigned drug
Study: NCT01848210
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coumarin + troxerutin placebo-matching tablets
Study: NCT04983524
Drug: Calcium Hydroxide
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gold standard control intracanal medicament
Study: NCT04592419
Drug: KSI-301
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal Injection
Study: NCT03389763
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a rate of infusion will be increased by 50% every 5 minutes
Study: NCT01411111
Drug: Rosuvastatin 10 mg
Normalized name: rosuvastatin 10 MG
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: days 1-14
Study: NCT01411111
Drug: GSK2190915 30mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1x30mg tablet, days 8-14
Study: NCT01411111
Drug: GSK2190915 100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1x100mg tablet, days 8-14
Study: NCT01661439
Drug: low molecular weight heparin (enoxeparine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1mg/kg enoxeparine SC daily from 1st day of the menstrual cycle and continue daily throughout the pregnancy after documentation of pregnancy,and stopped in absence of fetal cardiac activity.
Study: NCT03171415
Drug: RZL-012
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject receive a single-time injection. Multiple injections of RZL-012 are administered at 8-36 sites (0.1mL per site) into the abdominal subcutaneous fat.
Study: NCT03171415
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject receive a single-time injection. Multiple injections of the Placebo are administered at 8-36 sites (0.1mL per site) into the abdominal subcutaneous fat.
Study: NCT03803254
Drug: Folfox Protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin , fluorouracil, and leucovorin
Study: NCT03562949
Drug: Test Product
Normalized name: Patch test product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg
Study: NCT03562949
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Product
Study: NCT00160888
Drug: sodium nitroprusside, bradykinin, acetylcholine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03460158
Drug: Restylane-L®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restylane-L® for the indication for mid-to-deep dermal implantation for moderate to severe facial wrinkles and folds, such as nasolabial folds.
Study: NCT03460158
Drug: Restylane-L® Lyft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restylane-L® Lyft is for the indication of implantation into the deep dermis to superficial subcutis for the correction of moderate to severe facial folds and wrinkles, such as nasolabial folds and malars (cheek/cheek bone area).
Study: NCT03460158
Drug: Restylane Silk®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restylane Silk® is for the indication for submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids in patients over the age of 21.
Study: NCT01497132
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT02249117
Drug: BIWH 3
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02249117
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00201396
Drug: Mitomycin C,Epirubicin,Cisplatin,5-Fluorouracil,Leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction C/T + CCRT
Study: NCT03428945
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet identical to active drug
Study: NCT03496298
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for injection~Route of administration: SC
Study: NCT00942734
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet (5 mg) by mouth every day of each 28 day study cycle.
Study: NCT01341470
Drug: LY2495655
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered intravenously or subcutaneously
Study: NCT01341470
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered intravenously or subcutaneously
Study: NCT05167617
Drug: Vit D
Normalized name: Tri-Vit Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vit D was provided as 2000 IU daily for 3 and 6 months for patients who had mild and moderate HVD, respectively.
Study: NCT00108550
Drug: Inert placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive placebo capsule, one capsule on Day 1 with daily or weekly increase to 9 capsules daily by Week 5 of the 12-week trial
Study: NCT00451490
Drug: Fluoxentine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01257191
Drug: Diesel Exhaust Particles
Approvals — FDA: no, EMA: no, PMDA: no
Description: source: diesel engine
Study: NCT01257191
Drug: Fine Concentrated Ambient Particles
Approvals — FDA: no, EMA: no, PMDA: no
Description: source: concentrated ambient air
Study: NCT01257191
Drug: Ultrafine Concentrated Ambient Particles
Approvals — FDA: no, EMA: no, PMDA: no
Description: source: concentrated ambient air
Study: NCT04228627
Drug: Parentral Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correction of Iron stores without anaemia
Study: NCT00776568
Drug: Anti-hypertensive drugs
Normalized name: INVESTIGATIONAL ANTI-HYPERTENSIVE DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors, Ca channel blockers, Beta blockers, Diuretics, Cholesterol lowering agents and/or other drugs used alone or in combination, as prescribed.
Study: NCT00605176
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: cream, 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 2 weeks of daily treatment followed by 2 weeks of no treatment, and the second treatment cycle consisted of an additional 2 weeks of daily treatment followed by 8 weeks of no treatment.
Study: NCT01115062
Drug: Placebo Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo patch with the same properties as the Synera patch but without lidocaine/tetracaine will be administered for 30 minutes to the venipuncture site.
Study: NCT00883116
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01540344
Drug: HIPEC
Normalized name: Hyperthermic Intraperitoneal Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: bidirectional hyperthermic intraperitoneal chemotherapy (HIPEC) with 400 mg/sqm 5-FU + 20 mg/sqm folinic acid IV and 300 mg/sqm oxaliplatin IP
Study: NCT04536792
Drug: AG-946 Matched Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG-946 matched-placebo, oral encapsulated sugar spheres or tablets.
Study: NCT01467362
Drug: V0034CR01B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream Out of flares: 1 application bid (morning and evening) During flares: 1 application once a day (in the morning) Maximum 91 days
Study: NCT01467362
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream Out of flares: 1 application bid (morning and evening) During flares: 1 application once a day (in the morning) Maximum 28 days
Study: NCT04140292
Drug: Photodynamic therapy (PDT)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDT is a technique that combines a photosensitizing drug and an intense light source to kill tumor cells~Noninvasive fluorescence dosimetry may be performed on up to 6 lesions. Levulan Kerastick will be applied to each lesion and left to incubate for 30 minutes. Blue light (Blu-U device, 20 J/cm2, 33 minutes) will be administered.
Study: NCT02698930
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group given intravenous 0.4mcg/kg/h of normal saline from the beginning of the anesthesia to postoperative 1 day.
Study: NCT00684944
Drug: TRx0014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatin capsule, tid
Study: NCT02684396
Drug: TAK-648 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-648 placebo-matching solution
Study: NCT00065117
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00065117
Drug: leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04281524
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution of 70% 0.9% saline / 30% CSL312 diluent
Study: NCT00214812
Drug: HEC placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02054754
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02725411
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orally administered Celecoxib 100 mg twice daily for 56 weeks
Study: NCT01269476
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same volumes and frequency as active.
Study: NCT02938520
Drug: ABC/DTG/3TC STR - Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is a purple, biconvex, oval, tablet debossed with 572 Tri on one side, film-coated tablet contains abacavir sulphate equivalent to 600 mg of abacavir, dolutegravir sodium equivalent to 50 mg dolutegravir, and 300 mg of lamivudine. The inactive ABC/DTG/3TC tablet ingredients include D-mannitol, magnesium stearate, microcrystalline cellulose, povidone, and sodium starch glycolate.
Study: NCT02938520
Drug: DTG Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is a yellow, round, biconvex, 50 mg film-coated tablet debossed with SV 572 on one side and 50 on the other side. Each tablet of DTG also contains the following inactive ingredients: D-mannitol, microcrystalline cellulose, povidone K29/32, sodium starch glycolate, and sodium stearyl fumarate.
Study: NCT01921335
Drug: ARRY-380 Once Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARRY-380 will be administered daily once-daily) along with concurrent administration of trastuzumab on Day 1. PK sampling of ARRY-380 is planned on Day 15. Blood samples will be collected at pre-dosing, 2 hours (± 1 hour), and 6 hours (± 2 hours). The same time points will be collected for BID and QD schedules. On the PK collection day participants should fast one hour before and one hour after taking ARRY-380.
Study: NCT02243137
Drug: acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration: one dose of Acetylsalicylic Acid (300mg)
Study: NCT03393741
Drug: Taxane
Normalized name: Taxanes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxane is a chemotherapeutic agent and a standard drug for treatment in breast cancer targeting microtubules. This drug is typically infused as a single agent for breast cancer therapy.
Study: NCT03393741
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy is used to treat various stages of breast cancer.
Study: NCT00206245
Drug: AZD0865
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00981227
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral route
Study: NCT01609582
Drug: TAK-875 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-875 placebo-matching tablets
Study: NCT00118365
Drug: sulindac
Normalized name: Sulindac
DrugBank: Sulindac (DB00605)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT00572585
Drug: AEB071
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00572585
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01463982
Drug: Oratecan and Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oratecan in combination with Capecitabine~* Irinotecan HCl Tablet - Initial dose 10 mg/m2 (may be increased up to 20 mg/m2), Day1\~Day5~* HM30181AK Tablet - Fixed dose 15 mg, Day1\~Day5~* Capecitabine Tablet - Initial dose 800 mg/m2 (may be increased up to 1000 mg/m2), Day1\~Day14
Study: NCT01808248
Drug: SOF
Normalized name: Kasof
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir (SOF) 400 mg tablet administered orally once daily
Study: NCT01045512
Drug: fluvastatin
Normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40-80mg once daily
Study: NCT00821977
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003596
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00024349
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02245490
Drug: Matching placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01432028
Drug: Estradiol and Drospirenone
Normalized name: drospirenone / estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral estradiol 1mg and drospirenone 2 mg/day
Study: NCT04479748
Drug: Prednisolone Acetate 1% Oph Susp
Normalized name: PREDNISOLONE ACETATE 1% OPH SUSP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroid
Study: NCT01699828
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be lactose and encapsulated for blinding. A single capsule will be given.
Study: NCT00653016
Drug: norelgestromin; ethinyl estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01843309
Drug: Spironolactone 100mg
Normalized name: SPIRONOLACTONE 100MG TAB
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01843309
Drug: Spironolactone 200mg
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01843309
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00447161
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo
Study: NCT00425451
Drug: PerioChip Plus (Flurbiprofen +Chlorhexidine ), Flurbiprofen Chip, PerioChip (Chlorhexidine ) and Placebo Chip
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01114581
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given as 2 tablets
Study: NCT03568604
Drug: Prasterone
Normalized name: Prasterone
DrugBank: Prasterone sulfate (DB05804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6.5 vaginal insert prasterone (dehydroepiandrosterone)
Study: NCT03485027
Drug: the rechallenge regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: XELOX regimen: Oxaliplatin 130mg/m2, intravenous, on day 1; Capecitabine 1000mg/m2, oral, twice daily, continuously for 14 days; ±bevacizumab 7.5mg/kg, intravenous, on day 1; repeating every 3 weeks. FOLFOX regimen: Oxaliplatin 85mg/m2 on day 1; Calcium folinate 400mg/m2 on day 1; 5-FU 400mg/m2 on day 1; 5-FU 2.4g/m2, continuous intravenous infusion for 46 hours, ± Bevacizumab 5mg/kg or ± Cetuximab 500mg/m2, repeating every 2 weeks. FOLFIRI regimen: Irinotecan 180mg/m2 on day 1; Calcium folinate 400mg/m2 on day 1; 5-FU 400mg/m2 on day 1; 5-FU 2.4g/m2, continuous intravenous infusion for 46 hours; ± Bevacizumab 5mg/kg or ± Cetuximab 500mg/m2, repeating every 2 weeks. Irinotecan monotherapy regimen: Irinotecan 180mg/m2 on day 1, ± Bevacizumab 5mg/kg or ± Cetuximab 500mg/m2, repeating every 2 weeks. Raltitrexed contained regimen: Raltitrexed 3mg/m2 on day 1; ± Bevacizumab 7.5mg/kg, repeating every 3 weeks; Raltitrexed 2mg/m2 on day 1; ± Cetuximab 500mg/m2, repeating every 2 weeks.
Study: NCT02700815
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02700815
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02569307
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline added to TAU Minocycline will be administered in 200mg once daily dose
Study: NCT02569307
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo added to TAU
Study: NCT02569307
Drug: Minocycline Plus Omega-3 fatty acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline will be administered in 200mg once daily dose and Omega-3 fatty acid 1.2g taken as once daily dose
Study: NCT02246686
Drug: STW5-II (Iberogast N, BAY98-7410)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application over 12 weeks 20 drops three time daily
Study: NCT02246686
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application over 12 weeks 20 drops three time daily
Study: NCT01129323
Drug: Cyclophosphamide, Fludarabine, Rabbit ATG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine 30mg/m2/dose IV and cyclophosphamide 10mg/kg/dose IV are given once per day from day -5 to -2. rATG 1.5 mg/kg/dose IV is given from day -4 to -1.
Study: NCT00890942
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline 1 ml IM
Study: NCT01964872
Drug: Placebo: Parts 1a, 2, 3, and 4 (optional)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally matched to study drug
Study: NCT01386034
Drug: Citrulline and placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After receiving a 7-day oral supplementation with either citrulline or placebo, each subject will be admitted for a half day, after an overnight fast, and will receive a 5-h intravenous infusion of L-\[1-13C\]leucine. At regular intervals throughout the isotope infusion, blood will be obtained to measure 13C-enrichment in plasma a-keto-isocaproate, using gas chromatography-mass spectrometry. Simultaneously, 13C-enrichment will be measured in aliquots of expired air CO2 using isotope ratio mass spectrometry, and total CO2 production (VCO2) will be measured using direct calorimetry, respectively. Then the subject take no treatment for 13 days. The study will then be repeated a second time in an identical fashion, after a second 7-day period of oral supplementation with either citrulline or placebo.
Study: NCT01941901
Drug: Calcium electroporation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratumoral injection, once only treatment.
Study: NCT00115050
Drug: TMC114
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03445338
Drug: K0706
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study
Study: NCT01093196
Drug: Cyclophosphamide, Prednisone, Lenalidomide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction: 9 cycles every 28 days:Lenalidomide will be given orally at the dose of 25 mg/day for 21 days followed by a 7 days rest period (day 22 to 28;Cyclophosphamide will be given orally at the dose of 50 mg /day for 21 days followed by a 7 day rest period (days 1 to 28) in patients 65-75 years old and 50 mg every other day (days 1 to 20 followed by a 8 days rest period \[day 21 to 28\]) in patients older than 75 years.Prednisone will be given orally at the dose of 25 mg every other day (days 1 to 28.Each cycle will be repeated every 28 days, until any sign of disease progression(PD).
Study: NCT01124435
Drug: Carboplatin plus Celecoxib
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: celecoxib (200 mg tablets by mouth twice daily, day 1 to 28), associated to intravenous carboplatin (area under the curve (AUC) 5 over 30 to 60 minutes, every 28 days).
Study: NCT01632163
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:solution~Route of administration: subcutaneous injection
Study: NCT02899988
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT00176943
Drug: Aldara Cream 5%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03460990
Drug: VX-659/TEZ/IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received VX-659/TEZ/IVA orally once daily in the morning.